Shareholding Pattern Q1 2022-23
Shareholding Pattern Q1 2021-22
Shareholding Pattern Q2 2021-22
Shareholding Pattern Q3 2021-22
Shareholding Pattern Q4 2021-22
Shareholding Pattern Q1 2020-21
Shareholding Pattern Sep 30 2020
Shareholding Pattern Q3 Dec 31 2020
Shareholding Pattern Q4 2021
Shareholding Pattern Q1 2019-20
Shareholding Pattern Q2 FY 2020
Shareholding Pattern Q3 2019-20
Shareholding Pattern Q4 2019-20
Shareholding Pattern Q1 2018-19
Shareholding Pattern Q2 2018-19
Shareholding Pattern Q3 2018-19
Shareholding Pattern Q4 2018-19
Shareholding Pattern Q1 2017-18
Shareholding Pattern Q2 2017-18
Shareholding Pattern Q3 2017-18
Shareholding Pattern Q4 2017-18
Q3-Shareholding Pattern
Shareholding Pattern Q4 2016-17
Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020)
Unclaimed Dividend Details of 2018-19 (October 31, 2019)
Unclaimed Dividend Details of 2017-18 (October 31, 2018)
Unclaimed Dividend Details of 2016-17 (November 28, 2017)
We are building on our strengths to further extend our product portfolio and target fast-growing segments.
As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases.
As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community.
Laurus Synthesis 
Laurus Generics GmbH 
Laurus Generics Inc. 
